LAURA DAVIS: Open Payments
NPI 1780691063 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$988 in 34 payments from 14 companies in 2025. Trend: 2023 $906 · 2024 $2,245 · 2025 $988
Food & beverage: $988
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $213 |
| Merck Sharp & Dohme LLC | 5 | $133 |
| AstraZeneca Pharmaceuticals LP | 5 | $127 |
| Myriad Genetic Laboratories, Inc. | 2 | $99 |
| GlaxoSmithKline, LLC. | 4 | $86 |
| E.R. Squibb & Sons, L.L.C. | 3 | $81 |
| Novartis Pharmaceuticals Corporation | 2 | $55 |
| Astellas Pharma US Inc | 2 | $50 |
| PFIZER INC. | 2 | $41 |
| Daiichi Sankyo Inc. | 1 | $24 |
Products named: ELAHERE, KEYTRUDA, MYRISK, LYNPARZA, JEMPERLI, SCEMBLIX, IMFINZI, Veozah.
Industry payments across TX — which companies pay providers there.
